Can D. Aydogdu
Munich, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
ASO Visual Abstract: Preoperative Tumor-Informed ctDNA for Prediction of Nodal Metastases at Radical Cystectomy in Bladder Cancer.
Journal: Annals of surgical oncology
Published: August 05, 2026
Oncologic Outcomes in a Contemporary "PROTEUS-like" Cohort of High-risk Prostate Cancer Treated with Radical Prostatectomy Without Neoadjuvant Hormonal Therapy.
Journal: European urology open science
Published: August 02, 2026
Longitudinal circulating tumour DNA identifies patients at high risk of upstaging and recurrence in non-muscle-invasive bladder cancer.
Journal: BJU international
Published: July 02, 2026
Reducing complexity in International Bladder Cancer Group intermediate-risk non-muscle-invasive bladder cancer stratification: a three-factor approach.
Journal: BJU international
Published: April 02, 2026
Preoperative Tumor-Informed ctDNA for Prediction of Nodal Metastases at Radical Cystectomy in Bladder Cancer.
Journal: Annals of surgical oncology
Published: March 30, 2026
Epidemiological Trends and Germline Variant Analysis of Young-Onset Bladder Cancer.
Journal: Clinical genitourinary cancer
Published: March 06, 2026
Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications.
Journal: European urology
Published: February 20, 2026
Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS).
Journal: Cancer immunology, immunotherapy : CII
Published: February 16, 2026
Deep early tumour shrinkage in metastatic upper tract urothelial carcinoma treated with enfortumab vedotin plus pembrolizumab.
Journal: BJU international
Published: February 12, 2026
Radiosurgery in Upper Tract Urothelial Carcinoma (UTUC).
Journal: Cancers
Published: February 11, 2026
Baseline Sarcopenia is Associated With Overall Survival but Not Toxicity in Patients Receiving Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma.
Journal: Clinical genitourinary cancer
Published: February 02, 2026
Trophoblastic-Differentiated Urothelial Carcinoma: Real-World Sequencing and Clinical Implications.
Journal: Clinical genitourinary cancer
Published: January 30, 2026
Last Updated: 09/26/2026